Biological and in silico studies on synthetic analogues of tyrosine betaine as inhibitors of neprilysin, a drug target for the treatment of heart failure.

CONCLUSIONS: Tyrosine betaine remains as a starting point for the development of NEP inhibitors because of the low probability of BBB permeation and, consequently, of NEP inhibition at the Central Nervous System, which is associated to an increment in the Aβ levels and, accordingly, with a higher risk for the onset of Alzheimer's disease.
PMID: 29766796 [PubMed - as supplied by publisher]

Source: Current Pharmaceutical Design - May 14, 2018 Category: Drugs & Pharmacology Authors: Kawano DF, de Carvalho MR, Machado MFM, Carmona AK, Braga GUL, Carvalho I Tags: Curr Pharm Des Source Type: research